Applying Pharmacogenomics in Drug Therapy of Cardiovascular Disease
- 22 January 2022
- book chapter
- encyclopedia
- Published by Elsevier BV
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT ProjectClinical Pharmacology & Therapeutics, 2012
- Cardiovascular Pharmacogenomics: Current Status and Future Directions—Report of a National Heart, Lung, and Blood Institute Working GroupJournal of the American Heart Association, 2012
- Awareness and Utilization of BRCA1/2 Testing Among U.S. Primary Care PhysiciansAmerican Journal of Preventive Medicine, 2011
- Variability in GWAS analysis: the impact of genotype calling algorithm inconsistenciesThe Pharmacogenomics Journal, 2010
- Pharmacogenetics of warfarin: regulatory, scientific, and clinical issuesJournal of Thrombosis and Thrombolysis, 2007
- Pharmacogenomics: bench to bedsideNature Reviews Drug Discovery, 2004
- Variants of Toll-Like Receptor 4 Modify the Efficacy of Statin Therapy and the Risk of Cardiovascular EventsJournal of the American College of Cardiology, 2003
- Pharmacogenomics — Drug Disposition, Drug Targets, and Side EffectsThe New England Journal of Medicine, 2003
- Inheritance and Drug ResponseThe New England Journal of Medicine, 2003
- Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9Pharmacogenetics, 1994